PHARMAC
TE PĀTAKA WHAIORANGA

Pharmacology and Therapeutics Advisory Committee

Objective advice to Pharmac

www.pharmac.govt.nz

Pharmacology and Therapeutics Advisory Committee Provisional Recommendations 12 & 13 November 2026

Pharmac is piloting a new approach which will allow people to understand the advice we get, within 30 business days of advisory committee meetings.
More information about provisional recommendations is on Pharmac's website

We are releasing provisional recommendations only at this time, which share the high-level outcome of the advice recommendation. Further information, which will explain the recommendation, will be shared when the full meeting record is completed. Applicants / suppliers are given the opportunity to withhold the provisional recommendation until more information is available.

Summary of Provisional Recommendations

Pharmaceutical and Indication	Provisional Recommendation
Dienogest for people with endometriosis or adenomyosis, subject to Special Authority criteria.	Cost Neutral*
Relugolix with oestradiol and norethisterone acetate as a second-line or later hormonal treatment for people with endometriosis or adenomyosis, subject to Special Authority criteria.	Medium priority
Third-line vascular endothelial growth factor (anti-VEGF) treatments (faricimab or aflibercept) for wet age-related macular degeneration (wAMD) and diabetic macular oedema (DMO), subject to Special Authority criteria.	Cost Neutral*
Zolmitriptan for the treatment of migraine attacks.	Cost Neutral*
Diabetic Oral Feed 1 kcal/mL (Glucerna) for people with type 1 or 2 diabetes who are experiencing malnutrition and weight loss, subject to Special Authority criteria.	Cost Neutral*
Tacrolimus ointment for the treatment of atopic dermatitis where conventional therapies, including topical corticosteroids, have not provided an adequate response.	Declined
Tacrolimus ointment for the treatment of atopic dermatitis where topical corticosteroids are contraindicated, subject to Special Authority criteria.	High Priority
SGLT-2 inhibitors and GLP-1 receptor agonists to be used together for treatment of type 2 diabetes in those with high cardiovascular and renal risk, subject to Special Authority criteria.	High Priority
Budesonide, glycopyrronium bromide and formoterol fumarate triple inhaler (Brezti) for people living with difficult-to-control or severe asthma, subject to Special Authority criteria.	**Withheld

*Cost Neutral – The Committee has recommended this application be funded if the cost is neutral to the provision of the currently funded medicine(s), including the related health system costs

**Withheld provisional recommendation – the applicant / supplier has requested the recommendation not be released until full record is available.

More information about the agenda items considered at the recent Pharmacology and Therapeutics Advisory Committee meeting can be found on the Pharmac website

Released 27 November 2026